A Drug-Centric View of Drug Development: How Drugs Spread from Disease to Disease

Abstract

Drugs are often seen as ancillary to the purpose of fighting diseases. Here an alternative view is proposed in which they occupy a spearheading role. In this view, drugs are technologies with an inherent therapeutic potential. Once created, they can spread from disease to disease independently of the drug creator’s original intentions. Through the analysis of extensive literature and clinical trial records, it can be observed that successful drugs follow a life cycle in which they are studied at an increasing rate, and for the treatment of an increasing number of diseases, leading to clinical advancement. Such initial growth, following a power law on average, has a degree of momentum, but eventually decelerates, leading to stagnation and decay. A network model can describe the propagation of drugs from disease to disease in which diseases communicate with each other by receiving and sending drugs. Within this model, some diseases appear more prone to influence other diseases than be influenced, and vice versa. Diseases can also be organized into a drug-centric disease taxonomy based on the drugs that each adopts. This taxonomy reflects not only biological similarities across diseases, but also the level of differentiation of existing therapies. In sum, this study shows that drugs can become contagious technologies playing a driving role in the fight against disease. By better understanding such dynamics, pharmaceutical developers may be able to manage drug projects more effectively.

A review of validation strategies for computational drug repositioning

“…In recent years, the drug-repositioning field has gained substantial traction with both academics and pharmaceutical companies, both because of the lack of preclinical development and optimization, as well as the substantially reduced risk of unforeseen adverse events [ 1 ]. A search for ‘drug repositioning’ in PubMed reveals that the number of publications has grown rapidly from only 11 articles in 2007 to 274 in 2015.…”

Drugs for hyperlipidaemia may slow down the progression of hearing loss in the elderly: A drug repurposing study

“…Moreover, the rate of deterioration in hearing loss progresses slowly over a prolonged period of time. However, drug repurposing, which is the process of discovering and validating previously known and approved drugs for new indications, can reduce the costs, risks and timescale of drug development . Moreover, the use of secondary data sets can be cost‐effective and less risky.…”

Leveraging population-based clinical quantitative phenotyping for drug repositioning

“…Identifying new indications for previously approved drugs, known as drug repositioning, is an attractive alternative to the traditional drug discovery paradigm as previously approved drugs have substantially lower risk of unforeseen adverse events 1 . Computational drug repositioning builds on this premise by pre-screening for promising repositioning candidates, with current methods primarily relying on molecular data [2][3][4][5] and/or the biological literature [6][7][8][9][10] .…”